The most effective agent against treatment-resistant symptoms of schizophrenia is the atypical antipsychotic clozapine
+(22,
+23). Unlike earlier antipsychotics, which have a high affinity for dopamine D
2 receptors, clozapine has greater affinity for the serotonin (5-HT
1A, 5-HT
2, 5-HT
3), muscarinic, histamine, dopamine D
3, and dopamine D
4 receptors and blocks
N-methyl-
d-aspartic acid antagonists
+(18,
+19). Although all neuroleptics can cause seizures in susceptible individuals or when given in high doses, clozapine is the most proconvulsive of these agents
+(24). Clozapine blocks dopamine D
3 receptors in the nucleus accumbens more than in the caudate-putamen, and, in contrast to other antipsychotics, induces
c-fos expression in the accumbens shell but not in the caudate-putamen
+(25). Clozapine does not produce the extrapyramidal side effects associated with the earlier antipsychotics and with high doses of the newer atypical antipsychotics
+(16–
+18). Higher levels of dopamine in the nucleus accumbens and the islands of Calleja
+(26) and expression of dopamine D
3 receptors in the nucleus accumbens, the ventral striatal gateway from amygdala and hippocampus to thalamus and frontal lobes have been reported in brains from some schizophrenic patients
+(27). In one recent report, a higher level of dopamine D
3 receptors was reported from peripheral blood lymphocytes of unmedicated schizophrenic patients as well as those receiving neuroleptics
+(28). Polymorphisms of the dopamine D
3 receptor have been associated with schizophrenia
+(29). Clozapine has greater affinity for 5-HT
2A and dopamine D
4than for dopamine D
3 receptors. However, in contrast to agents that block dopamine D
2 and dopamine D
3 receptors, 5-HT
2A and dopamine D
4 antagonists are not effective against symptoms of schizophrenia
+(30). Unlike neuroleptics that principally block the dopamine D
2 receptor and cause a sustained and substantial increase in serum prolactin and Fos in the caudate-putamen, clozapine induces only a transient smaller increase in serum prolactin and elicits expression of Fos in the paraventricular nucleus of thalamus
+(31) and expression of Fos and
c-fos mRNA in the islands of Calleja in the basal forebrain
+(32). The possible significance of these phenomena will be discussed in the next section.